Admin_Adham
Jump to Key Points The FDA has approved Brytly (apraclonidine ophthalmic solution, 0.125%), a nonprescription eye drop solution, for the treatment of eye redness caused by minor irritations, according to the agency.
Brytly, manufactured by Alcon, is the first over-the-counter eye drop containing apraclonidine and is approved for adults and children ages 12 and older.
The FDA advises patients to remove contact lenses before using Brytly and to wait at least 10 minutes after applying the drops before reinserting them. Patients who are using other eye drops should wait 5 minutes between products, according to the release. The medication should not be used more than twice daily, the FDA said.
Apraclonidine is available in higher concentrations by prescription for patients who have glaucoma or plan to undergo some eye surgeries
- FDA approved Brytly (apraclonidine 0.125%) as OTC eye redness relief.
- Indication: redness from minor irritations; adults + children ≥12 years.
- First OTC apraclonidine product; higher-strength Rx apraclonidine exists for glaucoma/surgery.
- Remove contact lenses before use; wait ≥10 min before reinsertion.
- Limit dosing to ≤2x/day; stop if pain, vision changes, or symptoms >3 days.
Patients should stop using Brytly and consult a doctor if they experience eye pain, vision changes, continued redness or irritation, or if symptoms persist for more than 3 days or worsen.
